Myriad Genetics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

Myriad Genetics reported third-quarter 2026 financial results and said it raised the midpoint of its full-year 2026 revenue guidance. The company attributed its progress toward profitable growth and an improved financial profile to strong execution and operational advances, while continuing to focus on molecular diagnostic testing and precision medicine. The article provides no specific revenue or profit figures and reports no stock-price movement.